These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 26252117)
1. 'Financial toxicity' looms as cancer combinations proliferate. Morrison C Nat Biotechnol; 2015 Aug; 33(8):783-4. PubMed ID: 26252117 [No Abstract] [Full Text] [Related]
2. Obtaining financial support for patients receiving off-label drugs. Clancey JK; Card IC Oncol Nurs Forum; 2000 Jun; 27(5):769-70. PubMed ID: 10868389 [No Abstract] [Full Text] [Related]
3. Placing bets on biotech. Weintraub K Cancer Discov; 2011 Nov; 1(6):462. PubMed ID: 22586641 [No Abstract] [Full Text] [Related]
4. Expensive cancer therapies: unintended effects. Delude CM J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602 [No Abstract] [Full Text] [Related]
5. GlaxoSmithKline cancer drug threatens Herceptin market. Waltz E Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273 [No Abstract] [Full Text] [Related]
6. US hospitals object to changes in Genentech drug distribution. Furlow B Lancet Oncol; 2014 Dec; 15(13):e591. PubMed ID: 25499290 [No Abstract] [Full Text] [Related]
8. Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care? Zafar SY; Peppercorn JM J Clin Oncol; 2017 Jul; 35(19):2113-2116. PubMed ID: 28459612 [No Abstract] [Full Text] [Related]
9. Cancer drugs can be four times more costly in some wealthy countries than in others. Kmietowicz Z BMJ; 2015 Dec; 351():h6578. PubMed ID: 26637341 [No Abstract] [Full Text] [Related]
10. Cancer drug prices and the free-market forces. Kantarjian H; Zwelling L Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953 [No Abstract] [Full Text] [Related]
11. Market spiral pricing of cancer drugs. Light DW; Kantarjian H Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792 [No Abstract] [Full Text] [Related]
15. Sticker shock sharpens focus on biologics. McNeil C J Natl Cancer Inst; 2007 Jun; 99(12):910-2, 914. PubMed ID: 17565148 [No Abstract] [Full Text] [Related]
16. Improving the institutional submission and approval process for clinical research protocols in oncology. Camacho LH; Marubio L; Purdom MA; Leonard D; Hong DS; Moulder S; Pilat SR; Kurzrock R J Clin Oncol; 2007 Apr; 25(12):1632-3. PubMed ID: 17443009 [No Abstract] [Full Text] [Related]
17. Role of financial relationships in economic analyses of targeted therapies in oncology remains unclear. Conter HJ J Clin Oncol; 2012 Nov; 30(31):3895; author reply 3895. PubMed ID: 23008317 [No Abstract] [Full Text] [Related]
18. [Pharmacoeconomic aspects of breast cancer management]. Kolbin AS; Zagorodnikova KA Vopr Onkol; 2011; 57(5):604-8. PubMed ID: 22238930 [No Abstract] [Full Text] [Related]
19. The drug that could have been. Schultz S US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678 [No Abstract] [Full Text] [Related]